Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p247 | Genetics and Epigenetics | ECTS2016

Common variants in Rspo 1,2 and 3 do not associate with BMD in stratified subpopulations of the Odense Androgen Study and mutations in these genes are not a common cause of craniotubular hyperostosis

Fijalkowski Igor , Hendrickx Gretl , Boudin Eveline , Szilagyi Ingrid , Nielsen Torben , Andersen Marianne , Brixen Kim , Van Hul Wim

The R-spondins are a family of four small, secreted agonists of the Wnt signaling pathway. Growing evidence from both in vitro studies and in vivo models supports the major role of these proteins in the skeletal development processes. In humans, common genetic variation in the RSPO3 gene has been associated with BMD in large scale GWAS study.This study aimed at further investigation of the genetic and functional contributions of the R-s...

ba0005p284 | Nutrition | ECTS2016

Is bone equally responsive to calcium and vitamin D intake from food vs supplements? Use of 41Calcium tracer kinetic model

Van Loan Marta , Hillegonds Darren , Rogers Tara , Garrod Marjorie , Peerson Janet , Gertz Erik , Demmer Elieke , Buchholz Bruce

Few interventions directly compare equivalent calcium and vitamin D from dairy vs supplements on the same bone outcomes.Objectives and Methods: Using 41Ca tracer techniques, determine if 4 servings/d of dairy foods reduces Ca excretion more than an equivalent amount of Ca and vitamin D from supplements. Secondary objective was to evaluate the time course for change in Ca excretion.Design: In this crossover trial, postmen...

ba0005p431 | Other diseases of bone and mineral metabolism | ECTS2016

Bisphosphonate therapy in Langerhans cell histiocytosis: an international retrospective descriptive study

Chellapandian Deepak , Makras Polyzois , Kaltsas Gregory , van den Bos Cor , Carret Anne-Sophie , Weitzman Sheila , Egeler Maarten , Abla Oussama

Introduction: Langerhans cell histiocytosis (LCH) is a monoclonal disorder characterized by proliferation and accumulation of atypical Langerhans cells. Bone involvement is particularly destructive and to date, no standard of care exists. Bisphosphonates are osteoclast inhibitors that could target the multinucleated giant cells within the LCH lesions and might be used to alleviate bone pain and the progression of disease.Objective: To evaluate the effica...

ba0001pp436 | Osteoporosis: treatment | ECTS2013

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Recknor Christopher , Roux Christian , Ho Pei-Ran , Hall Jesse , Bone Henry , Bonnick Sydney , van den Bergh Joop , Ferreira Irene , Wagman Rachel , Brown Jacques P

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...

ba0002p185 | (1) | ICCBH2013

An unusual presentation of progressive osseous heteroplasia in a 7-year-old female child

Schrander D E , Welting T J , Schrander J J P , van Rhijn L W , Korver-Keularts I , Schrander-Stumpel C T R M

Background: Progressive osseous heteroplasia (POH) (OMIM 166350) is a rare autosomal dominant condition, characterized by heterotopic ossification of the skin, subcutaneous fat and deep connective tissue. This condition is distinct from Albright’s hereditary osteodystrophy or Mccune–Albright syndrome (AHO) (OMIM 103580) and fibrodysplasia ossificans progressiva (FOP) (OMIM 135100).Presenting problem: We present an unu...

ba0003oc4.1 | Genetics of bone disease | ECTS2014

PLS3 mutations in X-linked osteoporosis with fractures

Zillikens M Carola , van Dijk Fleur S , Micha Dimitra , Riessland Markus , Marcelis Carlo LM , de-Die Smulders Christine E , Milbradt Janine , Franken Anton A , Harsevoort Arjan J , Lichtenbelt Klaske D , van de Peppel J , Pruijs Hans E , Rubio-Gozalbo M Estela , Zwertbroek Rolf , Moutaouakil Youssef , Egthuijsen Jaqueline , van der Eerden B , Hammerschmidt Matthias , Bijman Renate , Semeins Cor M , Bakker Astrid D , Everts Vincent , Klein-Nulend Jenneke , Campos-Obando Natalia , Hofman Albert , te Meerman Gerard J , van Leeuwen JP , Verkerk Annemieke JMH , Uitterlinden Andre G , Maugeri Alessandra , Sistermans Erik A , Waisfisz Quinten , Meijers-Heijboer Hanne , Wirth Brunhilde , Simon Marleen EH , Pals Gerard

Background: We identified a family with early onset X-linked osteoporosis and fracturesMethods: We performed whole exome sequencing of the X chromosome in three affected members. After discovering a putative pathogenic variant we performed Sanger sequencing of all exons of this gene in other members of this family and in 95 unrelated men suspected of OI type I without COL1A1/2 mutations. We also genotyped a SNP in this gene (minor allele frequency 0.02) ...

ba0003ht5 | (1) | ECTS2014

Skin inflammation causes bone loss with reduced bone formation through systemic IL-17A release

Uluckan Ozge , Keller Johannes , Karbach Susanne , Croxford Andrew , Finzel Stephanie , Koenders Marije , Berg Wim Van Den , Amling Michael , Waisman Ari , Schett Georg , Wagner Erwin

Patients with chronic inflammatory diseases such as psoriasis are at high risk for developing osteoporosis. Psoriatic arthritis patients exhibit bone loss caused by increased bone resorption through activation of osteoclasts. However, it is not clear whether psoriasis can lead to bone loss in the absence of arthritis. Using mouse models with skin inflammation as well as psoriasis patient samples, we show that increased circulating IL-17A from the inflamed skin triggers bone lo...

ba0003pp113 | Cell biology: osteoblasts and bone formation | ECTS2014

Bone-anabolic effects of sulforaphane, a naturally occurring isothiocyanate on bone metabolism

Thaler Roman , Dudakovic Amel , Rucci Nadia , Maurizi Antonio , Sturmlechner Ines , Spitzer Silvia , Rumpler Monika , Van Wijnen Andre J , Teti Anna , Klaushofer Klaus , Varga Franz

Few drugs generate bone-stimulatory effects via epigenetic mechanisms. Modulation of CpG-residues hydroxymethylation in gene-promoters of key osteoblast-related factors (e.g., DLX5) induces their expression and increases osteoblast differentiation in vitro. The chemical properties of sulforaphane (SFN), a natural compound abundantly present in cruciferous vegetables like broccoli, suggest that it may have similar molecular and biological effects. Previous stu...

ba0003pp115 | Cell biology: osteoblasts and bone formation | ECTS2014

Epigenetic modifications and canonical WNT signaling enable direct programming of non-osteogenic cells into osteoblasts

Cho Young-Dan , Yoon Won-Joon , Woo Kyung-Mi , Baek Jeong-Hwa , Lee Gene , van Wijnen Andre J , Ryoo Hyun-Mo

Mesenchymal cells alter and retain their phenotype during skeletal development through activation or suppression of signaling pathways. For example, we have shown that Wnt3a only stimulates osteoblast differentiation in cells with intrinsic osteogenic potential (e.g., MC3T3-E1 pre-osteoblasts) and not in fat cell precursors or fibroblasts (respectively, 3T3-L1 pre-adipocytes or NIH3T3 fibroblasts). Wnt3a promotes osteogenesis in part by stimulating autocrine production of the ...